These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1015 related items for PubMed ID: 11729387

  • 1. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC.
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [Abstract] [Full Text] [Related]

  • 2. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [Abstract] [Full Text] [Related]

  • 6. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, Astorga Jiménez R.
    Rev Esp Med Nucl; 2005 Jul; 24(1):5-13. PubMed ID: 15701340
    [Abstract] [Full Text] [Related]

  • 9. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?
    Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F.
    Eur J Endocrinol; 2003 Oct; 149(4):293-300. PubMed ID: 14514343
    [Abstract] [Full Text] [Related]

  • 10. Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan.
    Kunawudhi A, Pak-art R, Keelawat S, Tepmongkol S.
    Clin Nucl Med; 2012 Jun; 37(6):561-7. PubMed ID: 22614187
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
    Lee J, Nah KY, Kim RM, Oh YJ, An YS, Yoon JK, An GI, Choi TH, Cheon GJ, Soh EY, Chung WY.
    J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
    [Abstract] [Full Text] [Related]

  • 13. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
    Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A.
    J Nucl Med; 2001 Oct; 42(10):1464-9. PubMed ID: 11585858
    [Abstract] [Full Text] [Related]

  • 14. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY.
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [Abstract] [Full Text] [Related]

  • 15. Role of 18F-Choline Positron Emission Tomography/Computed Tomography to Detect Structural Relapse in High-Risk Differentiated Thyroid Cancer Patients.
    Piccardo A, Trimboli P, Puntoni M, Foppiani L, Treglia G, Naseri M, Bottoni GL, Massollo M, Sola S, Ferrarazzo G, Bruzzone M, Catrambone U, Arlandini A, Paone G, Ceriani L, Cabria M, Giovanella L.
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [Abstract] [Full Text] [Related]

  • 16. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH, Jung DW, Pak KJ, Kim IJ, Kim HJ, Cho JK, Shin SC, Wang SG, Lee BJ.
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [Abstract] [Full Text] [Related]

  • 17. Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma.
    Prestwich RJ, Viner S, Gerrard G, Patel CN, Scarsbrook AF.
    Br J Radiol; 2012 Oct; 85(1018):e805-13. PubMed ID: 22972977
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ, Yoo IeR, O JH, Lin C, Lin Q, Kim SH, Chung SK.
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [Abstract] [Full Text] [Related]

  • 19. Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma.
    Zuijdwijk MD, Vogel WV, Corstens FH, Oyen WJ.
    Nucl Med Commun; 2008 Jul; 29(7):636-41. PubMed ID: 18528186
    [Abstract] [Full Text] [Related]

  • 20. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M.
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 51.